We analyzed the role of alloHCT in patients with AML depending on the ratio of mutant to wild-type FLT3 alleles.
According to a predefined cutoff for the allelic ratio for mutant to wild-type <em>FLT3-ITDem>, patients were grouped into high ratio (HR) and low ratio (LR) <em>FLT3-ITDem>.
AlloHCT improves EFS and OS in patients with HR<em>FLT3-ITDem> but only EFS in LR<em>FLT3-ITDem> AML.